Celgene Coporation, Senior Vice President
Shawn Cline Tomasello has 31 years of exceptional success in Pharma and Biotech positively impacting 15 brands, global expansion strategies, and strategic M&A evaluations and executions. She joined Celgene Corporation in 2005 and currently serves as Senior Vice President, Hematology and Oncology.
Prior to joining Celgene®, Shawn was the National Director, Rituxan® at Genentech, Inc. During her many years at Genentech, she held various leadership positions across the Cardiovascular, Endocrine, Pulmonary, and Oncology franchises. Prior to Genentech, Shawn also worked for Pfizer Laboratories and Miles Pharmaceuticals. Before joining Pharma, Shawn was with Procter & Gamble.
Shawn serves as a member of Celgene’s Global Franchise Management Board, Global Market Access Committee, Global Hematology Oncology Development Committee, and Global Talent Development Advisory Board. She has delivered historical results in Hematology and Oncology with the two largest brands in Hematology (Revlimid® and Rituxan®), impacting the lives of hundreds of thousands of patients with standard of care therapies. In the last eight years at Celgene, she has been instrumental in strategic decisions regarding global expansions and M&A evaluations leading to three acquisitions (Pharmion Corporation, Gloucester Pharmaceuticals, Inc., and Abraxis BioScience, Inc.) and many critical collaborations. In addition, she has led teams in the launch of six brands with eleven indications, representing a CAGR of 47.0%.
Shawn is a Board Member for BioNJ, Inc. She holds an M.B.A. from Murray State University in Murray, Kentucky and a B.S. in Marketing from University of Cincinnati. Shawn is also very active in her community, volunteering for the Healthcare Businesswomen’s Association and Family Promise®.